Tenderwize
Back to tender search

Discount Contract for Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 192 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-03 - Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

20/100

Opportunity Score

High riskLow complexity
SuppliesOpen
Why this score?

Opportunity

20 / 100

Complexity

30 / 100

Risk factors

Patent expiry or loss of market exclusivity terminates the contract automatically. Uncertain timeline may affect supply...

No estimated volume or value; financial benefit cannot be quantified.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Weak opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical product: Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))
  • Participation in Open House discount contract procedure under § 130c SGB V
Show full summary

Open House procedure for discount contracts (Rabattverträge) for the drug combination Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)) with German health insurance companies. Eligible pharmaceutical entrepreneurs can join at any time during the contract period (01.03.2025 – 28.02.2027). No estimated value, award criteria, or procurement documents were provided in the analysis.

Risks

Patent expiry or loss of market exclusivity terminates the contract automatically. Uncertain timeline may affect supply...

No estimated volume or value; financial benefit cannot be quantified.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG concerning the specific medicinal product.
  • Must have a valid marketing authorization for the product in Germany or be entitled to market it.

Eligibility

  • Must submit a self-declaration confirming eligibility and reliability (no criminal records, etc.).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Discount Contract for Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R))

The TK aims to conclude discount contracts with all eligible pharmaceutical entrepreneurs for the drug combination Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)). No exclusivity, individual negotiations, or award criteria. Contract duration max 24 months from 01.03.2025 to 28.02.2027. Patent expiry may terminate contract earlier.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Procurement Details

Publication date
20 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
42252-2025

Documents (1)

Similar tenders